ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
-0,61%
Bitcoin
69 306,18
-2,06%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Revelation Biosciences Inc (REVBW)

  7. Revelation Biosciences Inc (REVBW) Actualités

REVBW

Revelation Biosciences (REVBW)

Revelation Biosciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:REVBW
DateHeureSourceTitreSymboleSociété
16/05/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REVBWRevelation Biosciences Inc
10/05/202422h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:REVBWRevelation Biosciences Inc
15/08/202223h30GlobeNewswire Inc.Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate ProgressNASDAQ:REVBWRevelation Biosciences Inc
29/07/202217h45GlobeNewswire Inc.Revelation Biosciences Inc. Announces Closing of $5 Million Public OfferingNASDAQ:REVBWRevelation Biosciences Inc
26/07/202214h15GlobeNewswire Inc.Revelation Biosciences Inc. Announces Pricing of $5 Million Public OfferingNASDAQ:REVBWRevelation Biosciences Inc
23/07/202200h30GlobeNewswire Inc.Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
14/07/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
13/06/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis NASDAQ:REVBWRevelation Biosciences Inc
23/05/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
16/05/202222h01GlobeNewswire Inc.Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate ProgressNASDAQ:REVBWRevelation Biosciences Inc
06/04/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate UpdateNASDAQ:REVBWRevelation Biosciences Inc
30/03/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
24/03/202214h00GlobeNewswire Inc.Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
22/03/202214h00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLCNASDAQ:REVBWRevelation Biosciences Inc
15/03/202214h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
08/03/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at the 34th Annual Roth ConferenceNASDAQ:REVBWRevelation Biosciences Inc
07/02/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor ConferenceNASDAQ:REVBWRevelation Biosciences Inc
24/01/202214h00GlobeNewswire Inc.Revelation Biosciences Raises $7.76 Million in Equity FinancingNASDAQ:REVBWRevelation Biosciences Inc
20/01/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza InfectionNASDAQ:REVBWRevelation Biosciences Inc
18/01/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic RhinitisNASDAQ:REVBWRevelation Biosciences Inc
13/01/202219h54GlobeNewswire Inc.REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public CompanyNASDAQ:REVBWRevelation Biosciences Inc
11/01/202215h00GlobeNewswire Inc.Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public CompanyNASDAQ:REVBWRevelation Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:REVBW

Dernières Valeurs Consultées

NASDAQ
MSFT
Microsoft
EU
RNO
Renault
EU
ACA
Credit Agricole
EU
HO
Thales
NYSE
MCD
McDonalds
NYSE
NKE
Nike
EU
SGO
Cie de SaintGobain
EU
CS
Axa
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
EU
ML
Michelin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés